SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

H2L5186303

Item No. 14663

CAS Registry No.:	139262-76-3
Formal Name:	(Z,Z)-4,4'-[1,3-phenylenebis(oxy-4,1-phenyleneimino)]*bis*[4-oxo-2-butenoic acid
MF:	$C_{26}H_{20}N_2O_8$
FW:	488.5
Purity:	≥98%
UV/Vis.:	λ_{max}: 298 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



Laboratory Procedures

H2L5186303 is supplied as a crystalline solid. A stock solution may be made by dissolving the H2L5186303 in the solvent of choice. H2L5186303 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of H2L5186303 in these solvents is approximately 15 and 20 mg/ml, respectively.

H2L5186303 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, H2L5186303 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. H2L5186303 has a solubility of approximately 0.11 mg/ml in a 1:8 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

H2L5186303 is a selective lysophosphatidic acid 2 (LPA_2) receptor antagonist (IC_{50} = 9 nM in an LPA-elicited calcium mobilization assay).[1] It inhibits LPA_1 and LPA_3 at much higher concentrations (IC_{50}s = 27,354 and 4,504 nM, respectively).[1]

Reference

1. Fells, J. I., Tsukahara, R., Liu, J., *et al.* Structure-based drug design identifies novel LPA3 antagonists. *Bioorg. Med. Chem.* **17(21)**, 7457-7464 (2009).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/16/2016

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM